Navigation Links
Northwest Secures US$4.0 Million in Debt Financing
Date:5/9/2008

sis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent ovarian cancer. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at http://www.nwbio.com.

About the Al Rajhi Group

Al Rajhi Holdings W.L.L. and Al Rajhi Partners (together "Al Rajhi") represent the business interests of Sheikh Abdulrahman Saleh Al Rajhi and his immediate family in Saudi Arabia.

Al Rajhi is a private investment company and has investments in financial services, infrastructure, mining, healthcare, biotechnology, real estate, oil and gas. Key investments include Bank Al Bilad, DanaGas, Saudi Telecom, Saudi Cement and Procare hospitals. Khalid al Rajhi, CEO of Al Rajhi, is a director of each of these companies.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning the Company's plans to move its programs forward, statements regarding the Company's clinical trials and other business development activities, and statements regarding its fundraising activities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially fro
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
2. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
3. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
4. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
5. D-Pharm Secures Funding From Israels Chief Scientists Office
6. Aerovance Secures $20 Million in Debt Financing
7. Amarin Secures Global Intellectual Property Rights for Lipid Programs
8. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
9. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
10. Taligen Therapeutics Secures Series B Financing
11. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...es embedded with a telescope,promise to make it ea...do,other activities requiring sharper distance vis...scribe the advantages of these innovative glasses,...e May/June issue of,Journal of Biomedical Optics, ..."This new design has several advantages," says the...
(Date:7/24/2008)...ll/ -- American Oriental,Bioengineering, Inc. (NYS...,second quarter 2008 financial results on Monday, ...mpany will hold a conference call at 5:00 pm ET on...ter 2008 results. Listeners may,access the call by...rnational callers, access code: 41757592. A webcas...
(Date:7/24/2008).../- Poniard,Pharmaceuticals,...y focused,on oncology, today announced that it wil...second quarter results and provide a corporate upd...nt plan for picoplatin, the,Company,s lead product...ef,executive officer, Ronald A. Martell, president...
(Date:7/24/2008).../ -- Sagent Pharmaceuticals, Inc.,a privately-hel...d that it,has launched ceftazidime for injection, ...ntibiotic. Sagent will offer ceftazidime in 1,and ...vials. According to,IMS data, 2007 sales of inject...ately $45.7 million., "Sagent is proud to be prov...
Breaking Biology Technology:Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired 2Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired 3Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 2Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2
... , New Advances in Scanner Design for Super..., , , The Affymetrix Gen...r continued evolution of the GeneChip platform a...g continued feature size reduction for higher reso...ay-based products. The Affymetrix GeneChip Scanner...
... Tunable Parameters of the Affymetrix Expressi...oduction , The Statistical Algorithms in ...set data to generate expression values (Signals an...ciated p-values for every transcript represented o...re used to generate transcript Detection and Chang...
...rometry Application Note , Melissa Chen, ...CA , Introduction , Rapid ide...ixtures is one of the key objectives for the use o...ionally, this approach has utilized 3-dimensional ...LCQ Deca XP Plus and the Finnigan ProteomeX. Recen...
...rometry Application Report , Key Words Se... Equine serum Acepromazine , Gargi Chou...SA , Wayne Skinner and Scott Stanley...oduction , Acepromazine is widely used a...r to better facilitate handling of these large mam...
Other Biology Technology:The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 2The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 3The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 4The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 5The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 6The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 7The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 8The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 9The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 10Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 2Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 3Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 4Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 5Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 6Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 7Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 8Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 9Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 10Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 2Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 3Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 4Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 2Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 3Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 4
(Date:7/23/2008)...enewable fuel source could generate enough electri...,s entire consumption needs and lead to a signific...according to US research published today, Thursday...ntal Research Letters . , The journal paper, ,Co...erting Manure to Biogas, has implications for all...
(Date:7/23/2008)...llectively spend about $1 billion annually could p...ic tons of carbon dioxide per year for the next 25...about that much money to put an end to a tenth of ...e top contributors to greenhouse gas emissions, re...rogram could have potential to reduce global carbo...
(Date:7/23/2008)...ernationally renowned scientists from 12 countries...lia and India to address ancient microscopic foss...ng together the world,s best scientists in the fie...iam Schopf, founder and director of the UCLA Insti...or the Study of Evolution and the Origin of Life (...
(Date:7/23/2008)...ards and Technology (NIST) have developed a techni... in protein-based pharmaceuticals. This first syst... scientists can be assured that their instruments ...aggregates, a major concern because of its impact ...ufacturing. , Proteins, a main constituent of ma...
Breaking Biology News(10 mins):Cow power could generate electricity for millions 2Paying to save tropical forests could be a way to reduce global carbon emissions 2Paying to save tropical forests could be a way to reduce global carbon emissions 3Paying to save tropical forests could be a way to reduce global carbon emissions 4UCLA 'world summit' to explore ancient life on Earth, and beyond 2NIST trumps the clumps: Making biologic drugs safer 2Safer easier system for remote explosive detection 4506 1Safer easier system for remote explosive detection 4506 2CamelBak 28R 29 CEO Statement on BPA and Plastic Re Usable Water Bottles 16442 1Haemacure Reports on its annual general and special meeting of shareholders 16438 1Haemacure Reports on its annual general and special meeting of shareholders 16438 2Haemacure Reports on its annual general and special meeting of shareholders 16438 3Haemacure Reports on its annual general and special meeting of shareholders 16438 4Aerobic Exercise Keeps You Young 16434 1Aerobic Exercise Keeps You Young 16434 2
...ure climate shows that the Sahel region, which exp... in the 1990s, could experience wetter monsoons fo...n Africa is projected to intensify further. Oceani...e gases appears to be a factor in these expected 2...Hurrell of the National Center for Atmospheric Res...
...d other causes of Sick Building Syndrome may impro... American Phytopathological Society (APS). , Sick...which building occupants experience health problem... issues typically associated with SBS range from a...problems involving exposure to toxins. , Mold is a...
...in plant science. , Scientists have known since 1...ey,ve known of its dramatic effects on plant growt... scientists know how it works. , In this week,s Na...rk Estelle, Nihal Dharmasiri and Sunethra Dharmasi...influences how and when plant cells grow and divid...
...mols suppress the growth of human cell lines repre...ary, pancreas, brain and blood, and reduce tumors ...addition, Enigmols did not show side effects at ef... at the Georgia Institute of Technology, Emory Uni...re funded by the National Cancer Institute. , "Ma...
Other Biology News:Africa to take it on chin again with climate change 2Africa to take it on chin again with climate change 3What's really making you sick? Plant pathologists offer the science behind Sick Building Syndrome 2At long last, scientists figure out how plants grow 2Researchers find promising cancer-fighting power of synthetic cell-signaling molecule 2Researchers find promising cancer-fighting power of synthetic cell-signaling molecule 3
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST).
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES
LTQ XL Linear Ion Trap from Thermo Scientific
Biology Products: